---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-053541"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:28:07.440278+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics adopts limited-duration poison pill; rights expire March 11, 2026

## Summary
- Board adopted rights agreement on March 12, 2025; dividend of one right per share to holders of record March 25, 2025.
- Rights become exercisable at $12.64/right if a person acquires 10% (20% for passive investors) of stock without approval.
- Upon trigger, holders (excluding acquiring person) can buy shares at 50% discount; rights expire March 11, 2026.
- Existing holders above thresholds are grandfathered but cannot increase ownership without losing grandfathered status.
- Board may redeem rights at $0.001 each or exchange for common stock prior to trigger.

## SEC filing metadata
- accession: 0001193125-25-053541
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.03, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000119312525053541/0001193125-25-053541-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000119312525053541/d815684d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-053541
- JSON: https://secwatch.observer/filing/0001193125-25-053541.json
- Plain text: https://secwatch.observer/filing/0001193125-25-053541.txt

## Key facts
- Governance Changes
  PLIANT THERAPEUTICS, INC.: Adopted Certificate of Designation for Series A Junior Participating Preferred Stock in connection with stockholder rights agreement (effective 2025-03-13).
  - Change: charter amendment
  - Effective: 2025-03-13
  source text: In connection with the adoption of the Rights Agreement described in Item 3.03 of this Current Report, the Board approved a Certificate of Designation of Series A Junior Participating Preferred Stock, which designates the rights, preferences and privileges of 300,000 shares of a series of the Company’s preferred stock, par value $0.0001 per share, designated as Series A Junior Participating Preferred Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746473/000119312525053541/0001193125-25-053541-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.